{"id":4146,"date":"2025-04-09T07:00:00","date_gmt":"2025-04-09T07:00:00","guid":{"rendered":"https:\/\/swisspresse.com\/us-biosimilars-market-is-expected-to-reach-us-65-62-billion-by-2033\/"},"modified":"2025-04-09T07:00:00","modified_gmt":"2025-04-09T07:00:00","slug":"us-biosimilars-market-is-expected-to-reach-us-65-62-billion-by-2033","status":"publish","type":"post","link":"https:\/\/swisspresse.com\/en\/us-biosimilars-market-is-expected-to-reach-us-65-62-billion-by-2033\/","title":{"rendered":"US Biosimilars Market is expected to reach US$ 65.62 billion by 2033"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div style=\"float:left; margin: 5px 10px 5px 0px;\">\n<div style=\"float:left; margin: 0px 10px 5px 0px; text-align:left;width:200px;\">\n<div class=\"border\">\u00a0<\/div>\n<p><a href=\"#\" onclick='open(\"http:\/\/www.emailwire.com\/popup.php?image=files\/pr_images\/1_1744118684_1148495.png&amp;title=Company Profile Image\",\"\",\"width=400,height=400,resizable,scrollbars=no,status=0\");' style=\"text-decoration:none;\"><img decoding=\"async\" valign=\"top\" border=\"0\" title=\"US Biosimilars Market - DataM Intelligence\" src=\"http:\/\/www.emailwire.com\/files\/pr_images\/mid_thumbs\/1_1744118684_1148495.png\" width=\"200\"><br \/><span style=\"float:left;\">US Biosimilars Market &#8211; DataM Intelligence<\/span><\/a><\/p>\n<\/div>\n<p>(<a href=\"https:\/\/www.emailwire.com\">EMAILWIRE.COM<\/a>, April 09, 2025 )  Market Size<br \/>US biosimilars market size reached US$ 8.62 billion in 2024 and is expected to reach US$ 65.62 billion by 2033, growing at a CAGR of 25.5% during the forecast period 2025-2033.<\/p>\n<p>Download Free Sample: <a href=\"https:\/\/www.datamintelligence.com\/download-sample\/us-biosimilars-market\">https:\/\/www.datamintelligence.com\/download-sample\/us-biosimilars-market<\/a><\/p>\n<p>Market Dynamics<br \/>Rising FDA Approvals Propel Growth of the U.S. Biosimilars Market<br \/>The U.S. biosimilars market is witnessing strong growth, driven by an increasing number of FDA-approved products. The regulatory foundation laid by the Biologics Price Competition and Innovation Act (BPCIA) of 2009 has provided a well-defined pathway for biosimilar approvals, encouraging manufacturers to invest in development.<\/p>\n<p>As a result, the FDA has steadily expanded its biosimilars portfolio, giving patients access to more affordable treatment options while helping reduce overall healthcare costs. To date, 71 biosimilars have been approved by the FDA. The latest addition is Omlyclo (omalizumab-igec), approved on March 7, 2025.<\/p>\n<p>Read Our Report: <a href=\"https:\/\/www.datamintelligence.com\/research-report\/us-biosimilars-market\">https:\/\/www.datamintelligence.com\/research-report\/us-biosimilars-market<\/a><\/p>\n<p>Market Segments<br \/>\u0095\tBy Product Type (Monoclonal Antibodies, Recombinant Human Growth Hormone (rhGH), Insulin, Anti-coagulants, Erythropoietin, Granulocyte Colony Stimulating Factor, Follitropin, Interferons, Others)<br \/>\u0095\tBy Application (Oncology, Chronic Diseases, Autoimmune Diseases, Infectious Diseases, Growth Hormone Deficiency, Hematology, Others)<\/p>\n<p>Key Market Players<br \/>Key players are Amgen Inc., Pfizer Inc., Sandoz Group AG, Teva Pharmaceuticals USA, Inc., Biogen, Biocon Biologics Inc., Boehringer Ingelheim International GmbH, Samsung Biologics, Dr. Reddy\u0092s Laboratories Ltd. and Fresenius Kabi USA, LLC. <\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/emailwire.com\/release\/1148495-US-Biosimilars-Market-is-expected-to-reach-US-6562-billion-by-2033.html?rand=161\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0 US Biosimilars Market &#8211; DataM Intelligence (EMAILWIRE.COM, April 09, 2025 ) Market SizeUS biosimilars market size reached US$ 8.62 billion in 2024 and is expected to reach US$ 65.62 billion by 2033, growing at a CAGR of 25.5% during the forecast period 2025-2033. Download Free Sample: https:\/\/www.datamintelligence.com\/download-sample\/us-biosimilars-market Market DynamicsRising FDA Approvals Propel Growth of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4147,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16,64],"tags":[],"class_list":{"0":"post-4146","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-press-releases"},"_links":{"self":[{"href":"https:\/\/swisspresse.com\/en\/wp-json\/wp\/v2\/posts\/4146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/swisspresse.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/swisspresse.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/swisspresse.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/swisspresse.com\/en\/wp-json\/wp\/v2\/comments?post=4146"}],"version-history":[{"count":0,"href":"https:\/\/swisspresse.com\/en\/wp-json\/wp\/v2\/posts\/4146\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/swisspresse.com\/en\/wp-json\/wp\/v2\/media\/4147"}],"wp:attachment":[{"href":"https:\/\/swisspresse.com\/en\/wp-json\/wp\/v2\/media?parent=4146"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/swisspresse.com\/en\/wp-json\/wp\/v2\/categories?post=4146"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/swisspresse.com\/en\/wp-json\/wp\/v2\/tags?post=4146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}